Interaksi Eksenatid dan Insulin reguler (manusia)

Eksenatid dan Insulin reguler (manusia): kedua label peresepan menguraikan interaksi yang biasanya memerlukan pemantauan, perubahan dosis, atau pemberian jarak antardosis.

Moderat

Biasanya dapat dikelola dengan pemantauan atau perubahan dosis. Beri tahu apoteker Anda bahwa Anda menggunakan keduanya.

Apa kata label FDA

Dari label Eksenatid (Byetta) · berlaku sejak 2025-09-02

Moderat

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Reduction in the dose of insulin secretagogues or insulin may be necessary.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin Patients receiving BYETTA in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia including severe hypoglycemia [see Adverse Reactions (6) and Drug Interactions (7) ] .

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed

Dari label Insulin reguler (manusia) (AFREZZA) · berlaku sejak 2026-05-30

Moderat

For patients with type 2 diabetes mellitus, oral antidiabetic treatment dosage modifications may be needed.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

For patients with type 2 diabetes mellitus, dosage modifications of concomitant oral antidiabetic treatment may be needed [see Drug Interactions ( 7 )] .

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Risk Factors and Mitigation Strategies for Hypoglycemia The risk of hypoglycemia after use of AFREZZA is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal [See Clinical Pharmacology ( 12.3 )] .

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Dosage Modifications for Drug Interactions Dosage modification may be needed when: AFREZZA is used concomitantly with certain drugs that increase and/or decrease the glucose lowering effect [see Drug Interactions ( 7 )].

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

Clinically Significant Drug Interactions with AFREZZA Antidiabetic agents, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blocking Agents, Disopyramide, Fibrates, Fluoxetine, Monoamine Oxidase Inhibitors, Pentoxifylline, Pramlintide, Salicylates, Somatostatin Analogs (e.g., octreotide), and Sulfonamide Antibiotics Prevention or Management Monitor…

Interaksi obatberdasarkan golongan obatLihat label di DailyMed

Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.

Buka di pemeriksa

Bukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.